Skip to main content
Independent and nonpartisan. SaveYourState is a civic information resource. It is not a government website and is not affiliated with any government agency, party, or campaign.

New York · 2025 Regular Session · Bill

S 5421: Designates Xylazine as a schedule III depressant

In committee Official data

  1. Introduced
  2. In committee
  3. Passed one chamber
  4. Passed both chambers
  5. Enacted

Last official action: ·Record last updated:

Plain-language summary

S 5421 is a bill introduced in the New York Senate on February 21, 2025. According to its official title, it concerns: Designates Xylazine as a schedule III depressant. Primary sponsor: James Skoufis (Democratic). Most recent recorded action (January 7, 2026): REFERRED TO HEALTH.

Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written

Official summary

Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.

Designates Xylazine as a schedule III depressant.

Sponsors

Sponsors by party (alphabetical): Democratic 1

NameRolePartyChamberDistrict
James SkoufisPrimary sponsorDemocraticSenate42

“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.

Recent official actions

  1. REFERRED TO HEALTH
  2. REFERRED TO HEALTH

Sources

  1. Open States / Plural (data from the official legislature website)
  2. Official legislature source